91 related articles for article (PubMed ID: 22430591)
1. Peptides binding to prostate-specific antigen enhance its antiangiogenic activity.
Mattsson JM; Närvänen A; Stenman UH; Koistinen H
Prostate; 2012 Oct; 72(14):1588-94. PubMed ID: 22430591
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
3. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
Denmeade SR; Litvinov I; Sokoll LJ; Lilja H; Isaacs JT
Prostate; 2003 Jun; 56(1):45-53. PubMed ID: 12746846
[TBL] [Abstract][Full Text] [Related]
5. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic activity of PSA-derived peptides.
Chadha KC; Nair B; Godoy A; Rajnarayanan R; Nabi E; Zhou R; Patel NR; Aalinkeel R; Schwartz SA; Smith GJ
Prostate; 2015 Sep; 75(12):1285-99. PubMed ID: 25963523
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
[TBL] [Abstract][Full Text] [Related]
8. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy.
Li B; Zhang LJ; Zhang ZL; Long M; Ren JH; Lin F; Wang X; Wei JX; Dong K; Zhang HZ
Anticancer Drugs; 2011 Mar; 22(3):213-22. PubMed ID: 21150773
[TBL] [Abstract][Full Text] [Related]
9. Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity.
Mattsson JM; Ravela S; Hekim C; Jonsson M; Malm J; Närvänen A; Stenman UH; Koistinen H
PLoS One; 2014; 9(9):e107819. PubMed ID: 25237904
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
[TBL] [Abstract][Full Text] [Related]
11. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
[TBL] [Abstract][Full Text] [Related]
12. Antibody immunoglobulin G (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostate tumors: Part 1. A double immunofluorescence analysis.
Sinha AA; Sackrison JL; DeLeon OF; Wilson MJ; Gleason DF
Anat Rec; 1996 Aug; 245(4):652-61. PubMed ID: 8837723
[TBL] [Abstract][Full Text] [Related]
13. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography.
Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J
Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435
[TBL] [Abstract][Full Text] [Related]
14. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
15. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
16. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Fortier AH; Holaday JW; Liang H; Dey C; Grella DK; Holland-Linn J; Vu H; Plum SM; Nelson BJ
Prostate; 2003 Aug; 56(3):212-9. PubMed ID: 12772191
[TBL] [Abstract][Full Text] [Related]
17. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
18. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
[TBL] [Abstract][Full Text] [Related]
19. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
[TBL] [Abstract][Full Text] [Related]
20. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]